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There is a slight increase in incident diabetes risk with the 
use of statins, but benefits likely outweigh any adverse 
effects in those with moderate-to-high cardiovascular risk
Lokpal Bhatia, Christopher D Byrne
Statins are one of the most widely used drug classes, 
with approximately 50 million prescriptions dispensed in 
England alone in 2008. Their effi cacy and safety in sig-
nifi cantly reducing cardiovascular events in moderate-
to-high-risk patients has been well documented, both in 
primary and secondary prevention.1 Commonly reported 
side-effects include muscle aches and increases in liver 
enzymes, but, in general, statins are well tolerated with a 
low incidence of side-effects. However, the recent collab-
orative meta-analysis of 13 major placebo-controlled sta-
tin trials by Sattar and colleagues reports a 9% increased 
risk for incident diabetes over 4 years (OR 1.09; 95% CI 
1.02-1-17) in patients randomised to statins compared to 
those assigned to placebo. Heterogeneity between trials 
was low (I2=11%), suggesting that this risk appears to be a 
true class effect, despite known differences in lipophilic-
ity and metabolic clearance pathways between individual 
statin drugs.
Although these fi ndings are of concern, it is worth 
pointing out that all meta-analyses have inherent limita-
tions. Importantly, as acknowledged by Sattar and col-
leagues, there was inter- and intra-trial variability of the 
methods used to defi ne a diagnosis of incident diabetes, 
with some trials employing a physician-reported diagno-
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sis and others utilising fasting blood glucose measure-
ments. When the authors analysed the trials using only 
fasting glucose concentrations, the difference between 
statin and placebo groups was not statistically signifi -
cant, which the authors suggest may have been due to 
a type 2 statistical error attributable to limited power. 
Unfortunately, there were no available data on differences 
in baseline fasting glucose concentrations or family his-
tory of diabetes between randomisation groups, changes 
in body mass index from baseline to follow up, use of 
diabetogenic drugs or levels of blood pressure control 
within trials. Each of these factors could have infl uenced 
risk of incident diabetes and have affected heterogeneity 
between trials, and, in turn, potentially confounding the 
fi ndings, although in our opinion this is unlikely given 
that trials were randomised. It is noteworthy that in half 
of the analysed trials, incident diabetes was reported as a 
post hoc fi nding, rather than as a prespecifi ed end point. 
However, despite these limitations, the large numbers of 
patients analysed give good statistical power to the meta-
analysis; thus, the consistent fi nding of statin-induced 
diabetes between trials cannot be dismissed, suggesting 
that the fi nding is real and cannot be explained away 
by attributing it to chance, bias or any confounding 
effects.
Given that diabetes increases the risk of cardiovas-
cular mortality by two- to four-fold, we are potentially 
presented with a paradox of statin benefi t versus harm. 
It is worth noting that the absolute risk of diabetes docu-
mented within the meta-analysis is indeed very low; that 
is, treatment with a statin for 1000 patient years resulted 
in only one excess case of diabetes. Comparing to other 
cardiovascular drugs known to increase the risk of diabe-
tes (eg, beta-blockers and thiazide diuretics), statins are 
3 times less likely to cause diabetes.2 Importantly, statins 
are approximately 8 times more likely to prevent a car-
diovascular event than cause a case of incident diabetes 
and, therefore, the risk–benefi t ratio is undoubtedly still 
hugely in favour of statin therapy for at-risk groups.
How might statins infl uence glucose tolerance and 
cause diabetes? Possible mechanisms include (a) reduc-
tion in metabolites produced during cholesterol synthesis, 
which would normally upregulate Glut-4, and (b) indi-
rect inhibition of pancreatic insulin release.3 Interestingly, 
although there is a well-known positive correlation 
between  infl ammation and insulin resistance, high-dose 
statins worsened glycaemic control, despite reducing 
high-sensitivity CRP to a greater extent than standard-
dose statins.4 This dissociation between statin-induced 
improvements in markers of infl ammation and statin-
induced changes in glucose tolerance was also evident 
in the JUPITER trial of rosuvastatin, which suggests that 
the association between statins and incident diabetes 
represents a complex interplay of molecular, genetic and 
physiological factors that requires further understand-
ing. Although some of the mechanisms responsible for 
affecting glucose concentrations may be due to differing 
lipophilicity of statins, the degree of lipophilicity does not 
mediate the clinical effectiveness of statins to decrease 
risk of myocardial infarction and stroke. Moreover, large-
scale clinical trials have not shown any differential effects 
between hydrophilic (eg, pravastatin) and more lipophilic 
(eg, simvastatin, atorvastatin) statins on cardiovascular 
end points.
Should this meta-analysis alter our practice of statin 
prescribing? The simple answer is no, when considering 
individuals at moderate or high cardiovascular risk, or 
with documented disease. However, it should encourage 
us to be more vigilant in identifying patients at high risk 
of developing diabetes (eg, individuals with the metabolic 
syndrome), when assessing the risk–benefi t ratio of statin 
use in patients with only modest cardiovascular risk. It 
also emphasises the need to continue to recommend/sup-
port lifestyle change and monitor plasma glucose concen-
trations in patients on long-term statins. Any future statin 
trials should include incident diabetes or impaired glucose 
regulation as a prespecifi ed secondary end point.
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